Market Access/ News/ News FDA knocks back MEI’s plans for drug in troubled PI3K class Phil Taylor fda, MEI Pharma, novel targeted cancer treatments, Oncology, PI3K 0 Comment MEI Pharma and partner Kyowa Kirin have had to abandon plans to file for approval of their PI3K Share X FDA knocks back MEI’s plans for drug in troubled PI3K class https://pharmaphorum.com/news/fda-knocks-back-meis-plans-for-drug-in-troubled-pi3k-class/
fda, MEI Pharma, novel targeted cancer treatments, Oncology, PI3K
0 Comment
